Project Grant R01HL185377
Award Date 7/15/26
Completion Date 3/31/30
Dollars Obligated $677K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Oklahoma City, OK 73104, USA
Similar Awards
- Federal Project Grant Award Summary Baylor College of Medicine received a $508,290 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective July 1, 2026, through March 31, 2030. The award funds mechanistic research investigating the role of BHLHE40 in orchestrating mucosal CD8 T cell responses in sarcoidosis lungs. The research addresses critical knowledge gaps in sarcoidosis pathogenesis by examining CD8...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Children's Hospital of Philadelphia Research Institute a $889,804 Project Grant on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds basic and translational research investigating MED12 (Mediator Complex Subunit 12) as a novel regulator of vasculogenesis, with completion targeted for March 31, 2031. The research leverages a MED12-deficient zebrafish...
- Federal Project Grant Award Summary The University of Oklahoma Health Sciences Center received a $700,000 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025, through August 31, 2027. This award funds a two-year investigator-initiated research project focused on elucidating the molecular, cellular, and organism-level mechanisms by which endothelial tetraspanins inhibit...
- Federal Grant Award Summary Baylor College of Medicine received a $773,868 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, with a completion date of June 30, 2030. The award funds research to elucidate the mechanisms regulating inflammation in developing lungs, with a focus on regulatory T cells (Tregs) and their role in bronchopulmonary dysplasia-associated pulmonary...
- Summary of Federal Project Grant Award The National Heart, Lung, and Blood Institute (NHLBI) awarded Louisiana State University Health Sciences Center-Shreveport a Project Grant totaling $425,505 under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 15, 2025, with a completion date of May 31, 2030. This award funds research investigating the role of cell-specific programmed death-ligand 1 (PD-L1) in cardiac pathophysiology following ischemic injury and its...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Feinstein Institutes for Medical Research a Project Grant of $586,866 under the Cardiovascular Diseases Research program (CFDA 93.837) on May 15, 2026, with a completion date of February 28, 2030. This award funds research investigating the critical role of B-1A cells, an immunoregulatory B cell subset, in mitigating acute lung injury (ALI) and acute respiratory distress...
- Federal Project Grant Award Summary South Dakota State University received a $452,869 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective April 20, 2026, with completion targeted for January 31, 2031. The research focuses on elucidating the molecular mechanisms of lymphatic valve dysfunction and lymphedema development. The funded work will investigate how intraflagellar transport (IFT)...
- Federal Project Grant Award Summary Louisiana State University Health Sciences Center-Shreveport received a $248,679 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded February 18, 2026, with completion targeted for January 31, 2029. The award funds basic and translational research to elucidate the functional role and underlying mechanisms of HMGXB4 (high mobility group box domain containing 4), an...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $694,754 Project Grant to The Washington University, Office of Sponsored Research Services, effective August 1, 2025, through May 31, 2030, under the Cardiovascular Diseases Research program (CFDA 93.837). This research initiative focuses on developing a mechanism-based precision medicine approach for treating cardiomyopathies by connecting molecular and cellular contractile dysfunction to patient...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $811,885 to the J. David Gladstone Institutes under the Cardiovascular Diseases Research program (CFDA 93.837) on September 12, 2025. The award funds research to elucidate epigenomic mechanisms of cardiac fibrosis and heart failure pathogenesis, with a completion date of May 31, 2029. The research leverages novel genetic mouse models, advanced transcriptional and epigenomic...